KalVista Pharmaceuticals (KALV) Competitors $8.91 +0.14 (+1.60%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$8.91 0.00 (0.00%) As of 01/31/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends KALV vs. ARQT, INDV, IRON, GPCR, IMCR, TVTX, GLPG, EVO, KNSA, and MRVIShould you be buying KalVista Pharmaceuticals stock or one of its competitors? The main competitors of KalVista Pharmaceuticals include Arcutis Biotherapeutics (ARQT), Indivior (INDV), Disc Medicine (IRON), Structure Therapeutics (GPCR), Immunocore (IMCR), Travere Therapeutics (TVTX), Galapagos (GLPG), Evotec (EVO), Kiniksa Pharmaceuticals (KNSA), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry. KalVista Pharmaceuticals vs. Arcutis Biotherapeutics Indivior Disc Medicine Structure Therapeutics Immunocore Travere Therapeutics Galapagos Evotec Kiniksa Pharmaceuticals Maravai LifeSciences KalVista Pharmaceuticals (NASDAQ:KALV) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment and dividends. Which has better earnings and valuation, KALV or ARQT? KalVista Pharmaceuticals has higher earnings, but lower revenue than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKalVista PharmaceuticalsN/AN/A-$126.64M-$3.64-2.45Arcutis Biotherapeutics$59.61M26.00-$262.14M-$1.79-7.40 Do analysts prefer KALV or ARQT? KalVista Pharmaceuticals currently has a consensus target price of $23.80, indicating a potential upside of 167.12%. Arcutis Biotherapeutics has a consensus target price of $16.60, indicating a potential upside of 25.38%. Given KalVista Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe KalVista Pharmaceuticals is more favorable than Arcutis Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KalVista Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is KALV or ARQT more profitable? KalVista Pharmaceuticals has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -140.97%. KalVista Pharmaceuticals' return on equity of -103.92% beat Arcutis Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets KalVista PharmaceuticalsN/A -103.92% -88.06% Arcutis Biotherapeutics -140.97%-119.11%-45.95% Does the MarketBeat Community believe in KALV or ARQT? KalVista Pharmaceuticals received 282 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. Likewise, 74.78% of users gave KalVista Pharmaceuticals an outperform vote while only 65.26% of users gave Arcutis Biotherapeutics an outperform vote. CompanyUnderperformOutperformKalVista PharmaceuticalsOutperform Votes34474.78% Underperform Votes11625.22% Arcutis BiotherapeuticsOutperform Votes6265.26% Underperform Votes3334.74% Does the media prefer KALV or ARQT? In the previous week, KalVista Pharmaceuticals had 5 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 12 mentions for KalVista Pharmaceuticals and 7 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.04 beat KalVista Pharmaceuticals' score of 0.80 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KalVista Pharmaceuticals 2 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, KALV or ARQT? KalVista Pharmaceuticals has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. SummaryKalVista Pharmaceuticals beats Arcutis Biotherapeutics on 11 of the 16 factors compared between the two stocks. Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALV vs. The Competition Export to ExcelMetricKalVista PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$433.40M$6.87B$5.58B$9.12BDividend YieldN/A2.90%5.31%3.99%P/E Ratio-2.457.6680.0317.24Price / SalesN/A320.221,259.7283.26Price / CashN/A73.5045.9637.70Price / Book1.835.275.124.70Net Income-$126.64M$136.98M$111.40M$224.47M7 Day Performance3.48%-0.84%2.30%-0.19%1 Month Performance5.19%-0.02%3.13%0.57%1 Year Performance-43.39%7.51%24.60%20.35% KalVista Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALVKalVista Pharmaceuticals4.4449 of 5 stars$8.91+1.6%$23.80+167.1%-43.5%$433.40MN/A-2.45100Analyst ForecastNews CoverageARQTArcutis Biotherapeutics2.5373 of 5 stars$14.28+3.1%$16.60+16.2%+125.6%$1.68B$59.61M-8.01150Short Interest ↓Positive NewsINDVIndivior3.0562 of 5 stars$12.02+0.2%$16.00+33.1%-32.5%$1.66B$1.09B-300.421,164Analyst ForecastShort Interest ↑Positive NewsIRONDisc Medicine2.9415 of 5 stars$55.47-3.4%$88.90+60.3%-15.1%$1.64BN/A-13.8630Short Interest ↑GPCRStructure Therapeutics2.1617 of 5 stars$28.16-0.2%$81.29+188.7%-31.3%$1.61BN/A-38.06136Short Interest ↑IMCRImmunocore1.918 of 5 stars$32.41-1.8%$65.64+102.5%-54.5%$1.61B$249.43M-33.82320Analyst RevisionPositive NewsTVTXTravere Therapeutics1.313 of 5 stars$20.14-0.8%$24.00+19.2%+129.1%$1.57B$145.24M-4.43460GLPGGalapagos1.5832 of 5 stars$23.64-0.3%$30.75+30.1%-38.8%$1.56B$259.40M0.001,123EVOEvotec1.7653 of 5 stars$4.35+1.2%$5.93+36.4%-41.6%$1.54B$845.74M0.005,061Short Interest ↑News CoverageKNSAKiniksa Pharmaceuticals3.7505 of 5 stars$20.72+3.4%$36.60+76.7%+11.2%$1.49B$270.26M-147.17220Short Interest ↓MRVIMaravai LifeSciences4.6307 of 5 stars$5.63+0.1%$10.28+82.8%-15.0%$1.42B$288.95M-3.43610Insider Trade Related Companies and Tools Related Companies ARQT Alternatives INDV Alternatives IRON Alternatives GPCR Alternatives IMCR Alternatives TVTX Alternatives GLPG Alternatives EVO Alternatives KNSA Alternatives MRVI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KALV) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
